MedTrace Logo

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 604

Last updated 2025-08-28

No results posted yet for this study

Summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Advanced Solid Tumors

Interventions

DRUG

RMC-9805

Oral Tablets

DRUG

RMC-6236

Oral Tablets

Sponsors & Collaborators

  • Revolution Medicines, Inc.

    lead INDUSTRY

Principal Investigators

  • Revolution Medicines, Inc. · Revolution Medicines, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-07
Primary Completion
2026-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06040541 on ClinicalTrials.gov